Back to News
Market Impact: 0.38
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
Source: reuters.com
Healthcare & BiotechProduct LaunchesAntitrust & Competition
Novo Nordisk presented medical-meeting data showing that patients who switched from weight-loss injections to its daily Wegovy pill continued to lose weight. The results support Wegovy's potential in oral obesity treatment and could help Novo defend its competitive position against Eli Lilly in the fast-growing weight-loss drug market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
LLY-0.20
NVO0.62
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
- Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
- Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Research Workflows, Report Format Selection, and Interactive Synthesis
- Can ChatGPT Analyze a 10-K? A Verification Workflow